Amylmetacresol
(Synonyms: 戊甲酚) 目录号 : GC62842
Amylmetacresol is an antiseptic used to treat infections of the mouth and throat.
Cas No.:1300-94-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Amylmetacresol is an antiseptic used to treat infections of the mouth and throat.
| Cas No. | 1300-94-3 | SDF | |
| 别名 | 戊甲酚 | ||
| 分子式 | C12H18O | 分子量 | 178.27 |
| 溶解度 | DMSO : 100mg/mL | 储存条件 | 4°C, stored under nitrogen |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 5.6095 mL | 28.0473 mL | 56.0947 mL |
| 5 mM | 1.1219 mL | 5.6095 mL | 11.2189 mL |
| 10 mM | 0.5609 mL | 2.8047 mL | 5.6095 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Preoperative Amylmetacresol and dichlorobenzyl alcohol with lignocaine lozenge reduces postoperative sore throat following general anaesthesia using supraglottic airway devices: A double-blinded, randomised, placebo-controlled trial
Indian J Anaesth 2022 Jul;66(7):523-529.PMID:36111094DOI:10.4103/ija.ija_809_21.
Background and aims: Postoperative sore throat (POST) is an undesirable event reported in up to 62% of patients receiving general anaesthesia (GA). The incidence of POST following GA using a supraglottic airway device (SAD) is approximately 50%, with symptoms persisting up to 48 h. We examined the role of preoperative lozenges containing Amylmetacresol and dichlorobenzyl alcohol (AMC/DCBA) with lignocaine (Strepsils® Max Plus) in reducing the incidence and intensity of POST following GA using SAD. Methods: We conducted a prospective, double-blinded, randomised, placebo-controlled trial involving 88 adults receiving GA for elective surgery using SAD not exceeding 2 h. Patients received either Strepsils Max Plus (Strepsils-LA group) or a placebo before induction of GA. The incidence and intensity of sore throat, dysphagia and dysphonia was measured using the Verbal Rating Scale at 30 min (early) and at 24 h (late) after removal of SAD. Results: Overall POST incidence was lower in the Strepsils-LA group (27.7% versus 56.8%, P = 0.007). Patients in the Strepsils-LA group reported a significantly lower incidence of early POST (14.9% versus 37.8%, P = 0.016) with a lower mean ± standard deviation intensity score (0.17 ± 0.43 versus 0.49 ± 0.69, P = 0.016). Although the overall incidence of dysphagia was lower (23.4% versus 48.6%, P = 0.016), more patients experienced dysphonia in the Strepsils-LA group. AMC/DCBA with lignocaine lozenges showed a relative risk reduction of 50% and a number needed to treat of 4 in reducing POST. Conclusion: AMC/DCBA with lignocaine lozenges administered before GA using SAD is a simple and safe method to reduce the incidence and severity of POST.
Amylmetacresol/2,4-dichlorobenzyl alcohol, hexylresorcinol, or carrageenan lozenges as active treatments for sore throat
Int J Gen Med 2017 Feb 28;10:53-60.PMID:28280379DOI:10.2147/IJGM.S120665.
Up to 80% of sore throats are caused by viruses. Several over the counter products are available which provide symptomatic, not causal relief. For such lozenges, containing the antiseptics and local anesthetics Amylmetacresol (AMC) and 2,4-dichlorobenzyl alcohol (DCBA) or hexylresorcinol (HR), recently an additional virucidal effect was published. Therefore, we tested a set of Strepsils® lozenges, containing either HR (Max [#2]) or AMC/DCBA (Original [#3], Extra Strong [#4], Warm [#5], Orange and Vitamin C [#6], Sugar free Lemon [#7], Children/Strawberry [#8] and Soothing Honey and Lemon [#9]) for their antiviral efficiency against representatives of respiratory viruses known to cause sore throat: human rhinovirus (HRV) 1a, HRV8, influenza virus A H1N1n, Coxsackievirus A10, and human coronavirus (hCoV) OC43. The lozenges were tested head to head with Coldamaris® lozenges (#1), which contain the patented antiviral iota-carrageenan. None of the tested AMC/DCBA or HR containing lozenges shows any antiviral effectiveness against HRV8 at the tested concentrations, whereas all are moderately active against HRV1a. Only lozenge #5 shows any activity against hCoV OC43 and Coxsackievirus A10 at the tested concentrations. Similarly, only lozenge #3 is moderately active against influenza A H1N1n virus. The data indicates that neither the isolated effect of the active ingredients nor the pH but rather one or more of the excipients of the specific formulations are responsible for the antiviral effect of some of the AMC/DCBA or HR containing lozenges. In contrast, carrageenan-containing lozenges are highly active against all viruses tested. In another experiment, we showed that binding and inactivation of virus particles by iota-carrageenan are fast and highly effective. During the residence time of the lozenge in the mouth, the viral titer is reduced by 85% and 91% for influenza A virus and hCoV OC43, respectively. Carrageenan-containing lozenges are, therefore, suitable as causative therapy against viral infections of the throat.
[Synergistic Antibacterial Activity of Berberine in Combination with Amylmetacresol Against Enterococcus faecalis in vitro]
Sichuan Da Xue Xue Bao Yi Xue Ban 2020 Nov;51(6):749-754.PMID:33236595DOI:10.12182/20201160501.
Objective: To study the antibacterial effect of berberine combined with Amylmetacresol on Enterococcus faecalis. Methods: Both dilution method and live bacteria CFU were used to determine the minimum inhibitory concentration (MIC) of berberine and Amylmetacresol on E. faecalis. The killing effect of berberine and Amylmetacresol on planktonic E. faecalis was detected by suspension quantitative germicidal test and live/dead bacteria staining. The effects of berberine and Amylmetacresol on the structure of mature biofilm of E. faecalis was observed by scanning electron microscopy (SEM). The toxicity of berberine and Amylmetacresol on human oral keratinocytes (HOK) was determined by CCK-8 cell proliferation and cytotoxicity assay and cytotoxicity LDH assay. Results: The MIC of berberine was 512 μg/mL, and the MIC of Amylmetacresol was 0.023 3%. 512 μg/mL berberine and 0.002 33% Amylmetacresol had a weak killing effect on planktonic E. faecalis alone, while they showed a synergistic antibacterial effect in combination. Cell survival in the biofilm was only slightly changed by berberine and Amylmetacresol. The structure of biofilm was obviously changed by berberine and Amylmetacresol. 512 μg/mL berberine and 0.002 33% Amylmetacresol alone or in combination showed the survival rate was much higher than the injury rate, suggesting berberine and Amylmetacresol had a low cytotoxicity. Conclusion: Berberine and Amylmetacresol had synergism against E. faecalis, and the biological safety of the combination use was better.
Effectiveness of Amylmetacresol and 2,4-dichlorobenzyl alcohol throat lozenges in patients with acute sore throat due to upper respiratory tract infection: a systematic review protocol
JBI Database System Rev Implement Rep 2017 Apr;15(4):862-872.PMID:28398972DOI:10.11124/JBISRIR-2016-003034.
This review aims to determine the best available evidence related to the effectiveness of Amylmetacresol and 2,4-dichlorobenzyl alcohol throat lozenges in patients with acute sore throat due to upper respiratory tract infection (URTI). The objective is to examine the analgesic properties of Amylmetacresol and 2,4-dichlorobenzyl alcohol (AMC/DCBA) throat lozenge comparing with placebo for the relief of pain in patients with acute sore throat due to URTIs.The review question is:More specifically, the objectives are to.
Spectrum of bactericidal action of Amylmetacresol/2,4-dichlorobenzyl alcohol lozenges against oropharyngeal organisms implicated in pharyngitis
Int J Gen Med 2018 Nov 28;11:451-456.PMID:30568479DOI:10.2147/IJGM.S184406.
Purpose: Pharyngitis is commonly caused by a self-limiting upper respiratory tract infection (URTI) and symptoms typically include sore throat. Antibiotics are often inappropriately used for the treatment of pharyngitis, which can contribute to antimicrobial resistance, therefore non-antibiotic treatments which have broad antiseptic effects may be more appropriate. Amylmetacresol (AMC) and 2,4-dichlorobenzyl alcohol (DCBA) are present in some antiseptic lozenges and have established benefits in providing symptomatic relief and some in vitro antiviral action. Methods: Seven bacterial species associated with pharyngitis, namely Streptococcus pyogenes, Fusobacterium necrophorum, Streptococcus dysgalactiae subspecies equisimilis, Moraxella catarrhalis, Haemophilus influenza, Arcanobacterium haemolyticum and Staphylococcus aureus, were exposed to an AMC/DCBA lozenge dissolved in artificial saliva. In vitro bactericidal activity was measured as a log reduction in colony-forming units (CFUs). Results: Bactericidal activity was recorded against all organisms after 1 minute. Greater than 3 log10 reductions in CFUs were observed at 1 minute for S. pyogenes (log10 reduction CFU/mL ± SD, 5.7±0.1), H. influenza (6.1±0.1), A. haemolyticum (6.5±0.0) and F. necrophorum (6.5±0.0), at 5 minutes for S. dysgalactiae (6.3±0.0) and M. catarrhalis (5.0±0.9) and at 10 minutes for S. aureus (3.5±0.1). Conclusion: An AMC/DCBA lozenge demonstrated a greater than 99.9% reduction in CFUs against all tested species within 10 minutes, which is consistent with the time a lozenge remains in the mouth. Patients with uncomplicated bacterial pharyngitis may benefit from the antibacterial action of antiseptic AMC/DCBA lozenges. Furthermore, AMC/DCBA lozenges may be more relevant and appropriate than antibiotics for pharyngitis associated with a self-limiting viral URTI.